论文部分内容阅读
目的探讨血清、尿液中血管内皮抑素水平与膀胱癌发生、发展和预后的关系。方法采用ELISA方法检测92例膀胱癌患者(膀胱癌组)与50名体检健康者(对照组)血清和尿液血管内皮抑素水平。结果膀胱癌组血清和尿液血管内皮抑素水平高于对照组(P<0.01);膀胱癌患者尿液血管内皮抑素水平在有无淋巴结转移与不同病理分级上差异有统计学意义(P<0.05),血清血管内皮抑素水平在有无淋巴结转移上差异有统计学意义(P<0.01);血清和尿液血管内皮抑素水平诊断膀胱癌的AUC分别为0.694和0.857(P<0.01);血清和尿液中血管内皮抑素水平高的膀胱癌患者生存率明显低于血管内皮抑素水平低者(P<0.05)。结论血清和尿液血管内皮抑素水平可用于膀胱癌的辅助诊断和预后评估。
Objective To investigate the relationship between the level of endostatin in serum and urine and the occurrence, development and prognosis of bladder cancer. Methods Serum and urine levels of endostatin in 92 bladder cancer patients (bladder cancer group) and 50 healthy controls (control group) were detected by ELISA. Results The levels of serum endostatin in serum and urine in bladder cancer group were significantly higher than those in control group (P <0.01). The urinary endostatin level in bladder cancer patients was significantly different with or without lymph node metastasis (P <0.01). The AUC of serum and urinary endostatin level in diagnosis of bladder cancer were 0.694 and 0.857 (P <0.01), and the difference was statistically significant ). The survival rate of patients with bladder cancer with high level of endostatin in serum and urine was significantly lower than those with low level of endostatin (P <0.05). Conclusion Serum and urine endostatin levels can be used for the diagnosis and prognosis of bladder cancer.